Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer

• DOI: 10.4143/crt.2017.552
• Publication Date: 2018-01-24T04:31:15Z
• Authors: Soomin Ahn; Hyun Jeong Kim; Milim Kim; Yul Ri Chung; Eunyoung Kang; Eun-Kyu Kim; Se Hyun Kim; Yu Jung Kim; Jee Hyun Kim; In Ah Kim; So Yeon Park
• Keywords: Progesterone receptor; Adjuvant Therapy; Clinical Significance

Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications change cancer patients treated with PST.The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens 442 who had residual disease PST were included this study. The association between changes clinicopathologic features tumors, survival patients, analyzed.Estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2) changed 18 (4.1%), 80 (18.1%), 15 (3.4%) patients,respectively. ER PR mainly underwent positive negative conversion,whereas HER2 conversion. Negative conversion associated reduced disease-free survival. Moreover, a decline Allred score for post-PST significantly poor outcome patients. did not have prognostic significance. In multivariate analyses, be an independent adverse whole patient group, adjuvant endocrine therapy-treated subgroup, also pre-PST subgroup.ER little PST, whereas significantly. particular, revealed as indicator, suggesting that re-evaluation basic biomarkers mandatory proper management prognostication